Kimberly Desantis, MD
Family Medicine · Endwell, NYNPI 1376578724
Payments from drug & device makers
Across 656 payments — averaging $1722.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$968K
- Modernatx, Inc.$107K
- AstraZeneca$28K
- Astrazeneca UK Limited$23K
- AbbVie$2K
- Novo Nordisk$679
- plus $2K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 130 | $967,563 |
| Modernatx, Inc. | 263 | $107,477 |
| AstraZeneca | 5 | $27,651 |
| Astrazeneca UK Limited | 2 | $23,050 |
| AbbVie(2 entities) | 115 | $2,204 |
| Novo Nordisk | 45 | $679 |
| GSK | 20 | $223 |
| Lilly USA, LLC | 8 | $170 |
| Abbott | 10 | $153 |
| Amgen | 9 | $152 |
| Stryker | 1 | $139 |
| Phathom Pharmaceuticals, Inc. | 6 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $72 |
| Novartis | 4 | $53 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $46 |
| Corium, LLC | 4 | $46 |
| Merck | 2 | $42 |
| Irhythm Technologies, Inc. | 1 | $38 |
| Neurocrine Biosciences, Inc. | 2 | $37 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $31 |
| Corcept Therapeutics | 2 | $30 |
| Exact Sciences | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Boehringer Ingelheim | 2 | $27 |
| Verona Pharma, Inc. | 1 | $24 |
| Nevro Corp. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Gilead | 1 | $14 |
| Si-bone, Inc. | 2 | $14 |
| Bayer | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Radius Health, Inc. | 1 | $11 |
| Neuronetics, Inc. | 1 | $10 |
How this compares
$1,130,183 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other family medicine in Endwell
- Suchet PatelEndwell$23.3M
- Michael FedericoEndwell$1.4M
- Eric LorraineEndwell$740K
- Bruce BowlingEndwell$287K
- Duncan Sze-TuEndwell$227K
- Rekha PatelEndwell$161K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- James WildGowanda$2.2M
- Donald BrautigamWestfield$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.